Zobrazeno 1 - 10
of 206
pro vyhledávání: '"Goodchild SJ"'
Autor:
Johnson JP Jr; Department of In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Focken T; Department of Chemistry, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Karimi Tari P; Department of In Vivo Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Dube C; Department of In Vivo Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Goodchild SJ; Department of In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Andrez JC; Department of Chemistry, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Bankar G; Department of In Vivo Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Burford K; Department of Chemistry, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Chang E; Department of In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Chowdhury S; Department of Chemistry, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Christabel J; Department of In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Dean R; Department of In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., de Boer G; Department of Compound Properties, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Dehnhardt C; Department of Chemistry, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Gong W; Department of Chemistry, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Grimwood M; Department of Chemistry, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Hussainkhel A; Department of In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Jia Q; Department of Chemistry, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Khakh K; Department of In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Lee S; Department of Compound Properties, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Li J; Department of In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Lin S; Department of In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Lindgren A; Department of Compound Properties, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Lofstrand V; Department of Chemistry, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Mezeyova J; Department of In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Nelkenbrecher K; Department of In Vivo Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Shuart NG; Department of In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Sojo L; Department of Compound Properties, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Sun S; Department of Chemistry, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Waldbrook M; Department of In Vivo Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Wesolowski S; Department of Chemistry, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Wilson M; Department of Chemistry, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Xie Z; Department of In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Zenova A; Department of Chemistry, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Zhang W; Department of Chemistry, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Scott FL; Neurocrine Biosciences, San Diego, California, USA., Cutts AJ; Scientific Affairs, Xenon Pharmaceuticals, Inc, Burnaby, British Columbia, Canada., Sherrington RP; Executive Team, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Winquist R; Executive Team, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Cohen CJ; Executive Team, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Empfield JR; Executive Team, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada.
Publikováno v:
British journal of pharmacology [Br J Pharmacol] 2024 Oct; Vol. 181 (20), pp. 3993-4011. Date of Electronic Publication: 2024 Jun 24.
Autor:
Goodchild SJ; Department of Anesthesiology, Pharmacology and Therapeutics, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia, Canada., Ahern CA; Department of Molecular Physiology and Biophysics, University of Iowa, Iowa City, Iowa. Electronic address: christopher-ahern@uiowa.edu.
Publikováno v:
Biophysical journal [Biophys J] 2024 Jul 16; Vol. 123 (14), pp. 2167-2175. Date of Electronic Publication: 2024 Apr 24.
Autor:
Goodchild SJ; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC V5G 4W8, Canada., Shuart NG; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC V5G 4W8, Canada., Williams AD; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC V5G 4W8, Canada., Ye W; Neurocrine Biosciences, San Diego, California 92130, United States., Parrish RR; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC V5G 4W8, Canada., Soriano M; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC V5G 4W8, Canada., Thouta S; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC V5G 4W8, Canada., Mezeyova J; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC V5G 4W8, Canada., Waldbrook M; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC V5G 4W8, Canada., Dean R; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC V5G 4W8, Canada., Focken T; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC V5G 4W8, Canada., Ghovanloo MR; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC V5G 4W8, Canada.; Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC V5A 1S6, Canada.; Department of Neurology, Yale University, New Haven, Connecticut 06519, United States., Ruben PC; Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC V5A 1S6, Canada., Scott F; Neurocrine Biosciences, San Diego, California 92130, United States., Cohen CJ; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC V5G 4W8, Canada., Empfield J; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC V5G 4W8, Canada., Johnson JP; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC V5G 4W8, Canada.
Publikováno v:
ACS chemical neuroscience [ACS Chem Neurosci] 2024 Mar 20; Vol. 15 (6), pp. 1169-1184. Date of Electronic Publication: 2024 Feb 15.
Autor:
Hebbar M; Division of Neurology, Department of Pediatrics, BC Children's Hospital, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Al-Taweel N; Division of Neurology, Department of Pediatrics, BC Children's Hospital, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Gill I; Division of Neurology, Department of Pediatrics, BC Children's Hospital, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Boelman C; Division of Neurology, Department of Pediatrics, BC Children's Hospital, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Dean RA; Xenon Pharmaceuticals, 200-3650 Gilmore Way, Burnaby, BC, V5G 4W8, Canada., Goodchild SJ; Xenon Pharmaceuticals, 200-3650 Gilmore Way, Burnaby, BC, V5G 4W8, Canada., Mezeyova J; Xenon Pharmaceuticals, 200-3650 Gilmore Way, Burnaby, BC, V5G 4W8, Canada., Shuart NG; Xenon Pharmaceuticals, 200-3650 Gilmore Way, Burnaby, BC, V5G 4W8, Canada., Johnson JP Jr; Xenon Pharmaceuticals, 200-3650 Gilmore Way, Burnaby, BC, V5G 4W8, Canada., Lee J; Division of Neurology, Department of Pediatrics, BC Children's Hospital, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Michoulas A; Division of Neurology, Department of Pediatrics, BC Children's Hospital, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Huh LL; Division of Neurology, Department of Pediatrics, BC Children's Hospital, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Armstrong L; Department of Medical Genetics, BC Children's Hospital, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Connolly MB; Division of Neurology, Department of Pediatrics, BC Children's Hospital, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Demos MK; Division of Neurology, Department of Pediatrics, BC Children's Hospital, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. mdemos@cw.bc.ca.
Publikováno v:
BMC neurology [BMC Neurol] 2024 Jan 17; Vol. 24 (1), pp. 31. Date of Electronic Publication: 2024 Jan 17.
Autor:
Hebbar M; Division of Neurology, Department of Pediatrics, BC Children's Hospital, Faculty of Medicine, University of British Columbia, Vancouver BC., Al-Taweel N; Division of Neurology, Department of Pediatrics, BC Children's Hospital, Faculty of Medicine, University of British Columbia, Vancouver BC., Gill I; Division of Neurology, Department of Pediatrics, BC Children's Hospital, Faculty of Medicine, University of British Columbia, Vancouver BC., Boelman C; Division of Neurology, Department of Pediatrics, BC Children's Hospital, Faculty of Medicine, University of British Columbia, Vancouver BC., Dean RA; Xenon Pharmaceuticals, 200-3650 Gilmore Way, Burnaby, BC V5G 4W8., Goodchild SJ; Xenon Pharmaceuticals, 200-3650 Gilmore Way, Burnaby, BC V5G 4W8., Mezeyova J; Xenon Pharmaceuticals, 200-3650 Gilmore Way, Burnaby, BC V5G 4W8., Shuart NG; Xenon Pharmaceuticals, 200-3650 Gilmore Way, Burnaby, BC V5G 4W8., Johnson JP; Xenon Pharmaceuticals, 200-3650 Gilmore Way, Burnaby, BC V5G 4W8., Lee J; Division of Neurology, Department of Pediatrics, BC Children's Hospital, Faculty of Medicine, University of British Columbia, Vancouver BC., Michoulas A; Division of Neurology, Department of Pediatrics, BC Children's Hospital, Faculty of Medicine, University of British Columbia, Vancouver BC., Huh LL; Division of Neurology, Department of Pediatrics, BC Children's Hospital, Faculty of Medicine, University of British Columbia, Vancouver BC., Armstrong L; Department of Medical Genetics, BC Children's Hospital, Faculty of Medicine, University of British Columbia, Vancouver BC., Connolly MB; Division of Neurology, Department of Pediatrics, BC Children's Hospital, Faculty of Medicine, University of British Columbia, Vancouver BC., Demos MK; Division of Neurology, Department of Pediatrics, BC Children's Hospital, Faculty of Medicine, University of British Columbia, Vancouver BC.
Publikováno v:
Research square [Res Sq] 2023 Aug 08. Date of Electronic Publication: 2023 Aug 08.
Autor:
Kanyo R; Dept. of Pharmacology, Alberta Diabetes Institute, University of Alberta, 9-70 Medical Sciences Building, Edmonton, AB T6G 2H7, Canada., Lamothe SM; Dept. of Pharmacology, Alberta Diabetes Institute, University of Alberta, 9-70 Medical Sciences Building, Edmonton, AB T6G 2H7, Canada., Urrutia A; Dept. of Cellular and Molecular Biology, Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada., Goodchild SJ; Dept. of Cellular and Molecular Biology, Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada., Allison WT; Dept. of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada., Dean R; Dept. of Cellular and Molecular Biology, Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada., Kurata HT; Dept. of Pharmacology, Alberta Diabetes Institute, University of Alberta, 9-70 Medical Sciences Building, Edmonton, AB T6G 2H7, Canada.
Publikováno v:
Function (Oxford, England) [Function (Oxf)] 2023 May 04; Vol. 4 (4), pp. zqad021. Date of Electronic Publication: 2023 May 04 (Print Publication: 2023).
Autor:
Ghovanloo MR; Department of Neurology, Yale University School of Medicine, New Haven, CT, United States., Dib-Hajj SD; Department of Neurology, Yale University School of Medicine, New Haven, CT, United States., Goodchild SJ; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals Inc., Burnaby, BC, Canada., Ruben PC; Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada., Waxman SG; Department of Neurology, Yale University School of Medicine, New Haven, CT, United States.
Publikováno v:
Frontiers in physiology [Front Physiol] 2022 Nov 10; Vol. 13, pp. 1066455. Date of Electronic Publication: 2022 Nov 10 (Print Publication: 2022).
Autor:
Thouta S; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals Inc., Burnaby, BC, Canada., Waldbrook MG; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals Inc., Burnaby, BC, Canada., Lin S; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals Inc., Burnaby, BC, Canada., Mahadevan A; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals Inc., Burnaby, BC, Canada., Mezeyova J; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals Inc., Burnaby, BC, Canada., Soriano M; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals Inc., Burnaby, BC, Canada., Versi P; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals Inc., Burnaby, BC, Canada., Goodchild SJ; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals Inc., Burnaby, BC, Canada., Parrish RR; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals Inc., Burnaby, BC, Canada.; Department of Cell Biology and Physiology, Brigham Young University, Provo, UT, United States.
Publikováno v:
Frontiers in cellular neuroscience [Front Cell Neurosci] 2022 Sep 29; Vol. 16, pp. 964691. Date of Electronic Publication: 2022 Sep 29 (Print Publication: 2022).
Autor:
Ghovanloo MR; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC, Canada.; Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada., Goodchild SJ; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC, Canada., Ruben PC; Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada.
Publikováno v:
PloS one [PLoS One] 2022 Aug 01; Vol. 17 (8), pp. e0271801. Date of Electronic Publication: 2022 Aug 01 (Print Publication: 2022).
Autor:
Johnson JP; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada., Focken T; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada., Khakh K; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada., Tari PK; In Vivo Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada., Dube C; In Vivo Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada., Goodchild SJ; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada., Andrez JC; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada., Bankar G; In Vivo Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada., Bogucki D; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada.; Compound Properties, Xenon Pharmaceuticals Inc, Burnaby BC, Canada., Burford K; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada., Chang E; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada., Chowdhury S; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada., Dean R; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada., de Boer G; Compound Properties, Xenon Pharmaceuticals Inc, Burnaby BC, Canada., Decker S; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada., Dehnhardt C; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada., Feng M; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada., Gong W; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada., Grimwood M; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada., Hasan A; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada., Hussainkhel A; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada., Jia Q; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada., Lee S; Compound Properties, Xenon Pharmaceuticals Inc, Burnaby BC, Canada., Li J; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada., Lin S; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada., Lindgren A; Compound Properties, Xenon Pharmaceuticals Inc, Burnaby BC, Canada., Lofstrand V; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada., Mezeyova J; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada., Namdari R; Translational Drug Development, Xenon Pharmaceuticals Inc, Burnaby, Canada., Nelkenbrecher K; In Vivo Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada., Shuart NG; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada., Sojo L; Compound Properties, Xenon Pharmaceuticals Inc, Burnaby BC, Canada., Sun S; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada., Taron M; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada., Waldbrook M; In Vivo Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada., Weeratunge D; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada., Wesolowski S; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada., Williams A; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada., Wilson M; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada., Xie Z; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada., Yoo R; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada., Young C; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada., Zenova A; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada., Zhang W; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada., Cutts AJ; Scientific Affairs, Xenon Pharmaceuticals, Inc, Burnaby BC, Canada., Sherrington RP; Executive Team, Xenon Pharmaceuticals Inc, Burnaby, Canada., Pimstone SN; Executive Team, Xenon Pharmaceuticals Inc, Burnaby, Canada., Winquist R; Executive Team, Xenon Pharmaceuticals Inc, Burnaby, Canada., Cohen CJ; Executive Team, Xenon Pharmaceuticals Inc, Burnaby, Canada., Empfield JR; Executive Team, Xenon Pharmaceuticals Inc, Burnaby, Canada.
Publikováno v:
ELife [Elife] 2022 Mar 02; Vol. 11. Date of Electronic Publication: 2022 Mar 02.